EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early experience with sotatercept in adult patients with repaired and unrepaired congenital heart disease and pulmonary hypertension

Hans Gao, Richard Channick, Rajan Saggar, Michael Troy, Jeannette Lin, Gentian Lluri, Leigh Reardon, Jamil Aboulhosn

International Journal of Cardiology Congenital Heart Disease · 2026-12 · 26 · 100721

DOI: 10.1016/j.ijcchd.2026.100721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cardiology Congenital Heart Disease, 2026-12. Verfasst von Hans Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ahmanson/UCLA Adult Congenital Heart Disease Center, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Ang…. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulmonary arterial hypertension associated with congenital heart disease (ACHD-PAH) is a condition underrepresented in initial clinical trials investigating sotatercept, a first-in-class activin signaling inhibitor. Patients with unrepaired defects or complex congenital heart disease were excluded from these trials. Here, we describe real-world outcomes in a cohort of ACHD-PAH patients treated with sotatercept.

Methods

A single-center retrospective review was performed of 14 adults with ACHD-PAH initiated on sotatercept between May 2024 and January 2026. Patients had heterogeneous congenital anatomy; with half having unrepaired defects. Paired pre- and post-treatment measures were compared, and each patient served as their own control, over a median follow-up of 542 days.

Results

Eleven of 14 patients (79%) continued therapy. Three patients discontinued: one for epistaxis and two for clinical deterioration leading to heart-lung transplant listing. Adverse effects occurred in 50% of patients, most commonly epistaxis (43%). Hemoglobin increased by a median of 1.5 g/dL (p = 0.002). Symptomatic improvement was reported by 79%, and 29% improved by at least one WHO functional class. Exertional oxygen-saturation nadir improved in 71%. Echocardiography showed favorable subpulmonary ventricular remodeling, with increased fractional area change (+5.0%, p = 0.020) and reductions in right ventricular basal, mid-chamber, and longitudinal dimensions (all p ≤ 0.03). Lack of response was associated with advanced disease, pulmonary veno-occlusive physiology, and systemic ventricular dysfunction.

Conclusions

In this cohort of ACHD-PAH patients, sotatercept was generally well-tolerated and was associated with symptomatic improvement and echocardiographic signs of favorable ventricular remodeling.

Schlagwörter

Stichwörter der Autor:innen

Activin signaling inhibitorAdult congenital heart diseaseEisenmenger syndromePulmonary arterial hypertensionRight ventricular remodelingSotatercept

Autor:innen und Institutionen

  • Ahmanson/UCLA Adult Congenital Heart Disease Center, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Zitieren

APA

Gao, H., Channick, R., Saggar, R., Troy, M., Lin, J., Lluri, G., Reardon, L., & Aboulhosn, J. (2026). Early experience with sotatercept in adult patients with repaired and unrepaired congenital heart disease and pulmonary hypertension. International Journal of Cardiology Congenital Heart Disease, 26, 100721. https://doi.org/10.1016/j.ijcchd.2026.100721

Vancouver

Gao H, Channick R, Saggar R, Troy M, Lin J, Lluri G, et al. Early experience with sotatercept in adult patients with repaired and unrepaired congenital heart disease and pulmonary hypertension. International Journal of Cardiology Congenital Heart Disease. 2026;26:100721. doi:10.1016/j.ijcchd.2026.100721

BibTeX
@article{Gao2026,
  author = {Gao, Hans and Channick, Richard and Saggar, Rajan and Troy, Michael and Lin, Jeannette and Lluri, Gentian and Reardon, Leigh and Aboulhosn, Jamil},
  title = {Early experience with sotatercept in adult patients with repaired and unrepaired congenital heart disease and pulmonary hypertension},
  journal = {International Journal of Cardiology Congenital Heart Disease},
  year = {2026},
  volume = {26},
  pages = {100721},
  doi = {10.1016/j.ijcchd.2026.100721}
}
Kostenlos starten →